157 related articles for article (PubMed ID: 10673736)
1. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia.
Wall AM; Gajjar A; Link A; Mahmoud H; Pui CH; Relling MV
Leukemia; 2000 Feb; 14(2):221-5. PubMed ID: 10673736
[TBL] [Abstract][Full Text] [Related]
2. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities.
Foster JH; Thompson PA; Bernhardt MB; Margolin JF; Hilsenbeck SG; Jo E; Marquez-Do DA; Scheurer ME; Schafer ES
Cancer Chemother Pharmacol; 2019 Feb; 83(2):349-360. PubMed ID: 30488179
[TBL] [Abstract][Full Text] [Related]
4. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables.
Seidel H; Andersen A; Kvaløy JT; Nygaard R; Moe PJ; Jacobsen G; Lindqvist B; Slørdal L
Leuk Res; 2000 Mar; 24(3):193-9. PubMed ID: 10739001
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of elimination and tolerance of high dose of methotrexate (3 g/m2) in children with standard-risk acute lymphoblastic leukemia].
Cwliklińska M; Balwierz W; Nowak J; Stanuch H
Przegl Lek; 2006; 63(1):15-20. PubMed ID: 16892893
[TBL] [Abstract][Full Text] [Related]
7. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia.
Kinoshita A; Kurosawa Y; Kondoh K; Suzuki T; Manabe A; Inukai T; Sugita K; Nakazawa S
Cancer Chemother Pharmacol; 2003 Mar; 51(3):256-60. PubMed ID: 12655445
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
9. Renal function and methotrexate clearance in children with newly diagnosed leukemia.
Murry DJ; Synold TW; Pui CH; Rodman JH
Pharmacotherapy; 1995; 15(2):144-9. PubMed ID: 7624260
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetic analysis of high-dose methotrexate treatments in children with hematologic malignancies].
Csordás K; Eipel O; Hegyi M; Csóka M; Pap E; Kovács G
Orv Hetil; 2011 Oct; 152(40):1609-17. PubMed ID: 21945870
[TBL] [Abstract][Full Text] [Related]
12. [Population pharmacokinetics of high-dose methotrexate administered in 329 children with acute lymphoblastic leukemia].
Zhang CY; Gu J; Li YZ; Lu W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):106-10. PubMed ID: 18315911
[TBL] [Abstract][Full Text] [Related]
13. Systemic methotrexate exposure is greater after intrathecal than after oral administration.
Bostrom BC; Erdmann GR; Kamen BA
J Pediatr Hematol Oncol; 2003 Feb; 25(2):114-7. PubMed ID: 12571461
[TBL] [Abstract][Full Text] [Related]
14. Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments.
Pauley JL; Panetta JC; Crews KR; Pei D; Cheng C; McCormick J; Howard SC; Sandlund JT; Jeha S; Ribeiro R; Rubnitz J; Pui CH; Evans WE; Relling MV
Cancer Chemother Pharmacol; 2013 Aug; 72(2):369-78. PubMed ID: 23760811
[TBL] [Abstract][Full Text] [Related]
15. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
16. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.
Evans WE; Relling MV; Rodman JH; Crom WR; Boyett JM; Pui CH
N Engl J Med; 1998 Feb; 338(8):499-505. PubMed ID: 9468466
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia.
Medellin-Garibay SE; Hernández-Villa N; Correa-González LC; Morales-Barragán MN; Valero-Rivera KP; Reséndiz-Galván JE; Ortiz-Zamudio JJ; Milán-Segovia RDC; Romano-Moreno S
Cancer Chemother Pharmacol; 2020 Jan; 85(1):21-31. PubMed ID: 31673826
[TBL] [Abstract][Full Text] [Related]
18. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
19. Effect of Body Fat on Population Pharmacokinetics of High-Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia.
Orgel E; Nabais T; Douglas C; Mittelman SD; Neely M
J Clin Pharmacol; 2021 Jun; 61(6):755-762. PubMed ID: 33314168
[TBL] [Abstract][Full Text] [Related]
20. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach.
Odoul F; Le Guellec C; Lamagnère JP; Breilh D; Saux MC; Paintaud G; Autret-Leca E
Fundam Clin Pharmacol; 1999; 13(5):595-604. PubMed ID: 10520733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
